1. Home
  2. BCAB vs KUKE Comparison

BCAB vs KUKE Comparison

Compare BCAB & KUKE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • BCAB
  • KUKE
  • Stock Information
  • Founded
  • BCAB 2007
  • KUKE 2002
  • Country
  • BCAB United States
  • KUKE China
  • Employees
  • BCAB N/A
  • KUKE N/A
  • Industry
  • BCAB Medicinal Chemicals and Botanical Products
  • KUKE Other Consumer Services
  • Sector
  • BCAB Health Care
  • KUKE Real Estate
  • Exchange
  • BCAB Nasdaq
  • KUKE Nasdaq
  • Market Cap
  • BCAB 96.2M
  • KUKE 49.8M
  • IPO Year
  • BCAB 2020
  • KUKE 2021
  • Fundamental
  • Price
  • BCAB $2.08
  • KUKE $0.90
  • Analyst Decision
  • BCAB Strong Buy
  • KUKE
  • Analyst Count
  • BCAB 2
  • KUKE 0
  • Target Price
  • BCAB $6.00
  • KUKE N/A
  • AVG Volume (30 Days)
  • BCAB 1.6M
  • KUKE 834.1K
  • Earning Date
  • BCAB 11-08-2024
  • KUKE 11-05-2024
  • Dividend Yield
  • BCAB N/A
  • KUKE N/A
  • EPS Growth
  • BCAB N/A
  • KUKE N/A
  • EPS
  • BCAB N/A
  • KUKE N/A
  • Revenue
  • BCAB N/A
  • KUKE $14,784,158.00
  • Revenue This Year
  • BCAB N/A
  • KUKE N/A
  • Revenue Next Year
  • BCAB N/A
  • KUKE N/A
  • P/E Ratio
  • BCAB N/A
  • KUKE N/A
  • Revenue Growth
  • BCAB N/A
  • KUKE N/A
  • 52 Week Low
  • BCAB $1.14
  • KUKE $0.47
  • 52 Week High
  • BCAB $4.02
  • KUKE $4.07
  • Technical
  • Relative Strength Index (RSI)
  • BCAB 55.80
  • KUKE 56.06
  • Support Level
  • BCAB $1.87
  • KUKE $0.47
  • Resistance Level
  • BCAB $2.13
  • KUKE $1.00
  • Average True Range (ATR)
  • BCAB 0.12
  • KUKE 0.16
  • MACD
  • BCAB 0.00
  • KUKE 0.03
  • Stochastic Oscillator
  • BCAB 68.90
  • KUKE 84.92

About BCAB BioAtla Inc.

BioAtla Inc is a clinical-stage biopharmaceutical company. The company is engaged in the development of a novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its pipeline products comprise mecbotamab vedotin (BA3011), ozuriftamab vedotin (BA3021), and evalstotug (BA3071), and its Phase 1 clinical trial of BA3182 (CAB-EpCAM x CAB-CD3) and Bispecific antibody programs.

About KUKE Kuke Music Holding Limited

Kuke Music Holding Ltd provides classical music licensing, subscription, and education services in China. The company licenses its music content to online music entertainment platforms, such as Tencent Music Entertainment Group, digital music service providers, such as NetEase Cloud Music, as well as film and TV production companies, airlines, and smart hardware companies. Users can access the platform through the website, mobile app, and smart music devices.

Share on Social Networks: